NasdaqGS:RVMDBiotechs
How Investors Are Reacting To Revolution Medicines (RVMD) Pancreatic Cancer Data For RAS G12D Inhibitor
In early July 2026, Revolution Medicines reported Phase 1/2 data showing that its investigational RAS(ON) G12D inhibitor zoldonrasib, alone and in combinations, delivered high response and disease control rates with manageable safety in patients with metastatic pancreatic ductal adenocarcinoma.
Because there are currently no approved targeted therapies for RAS G12D cancers, these early results position zoldonrasib-based regimens as potentially important additions to treatment options if...